127
Participants
Start Date
May 15, 2019
Primary Completion Date
March 15, 2024
Study Completion Date
September 26, 2024
Regorafenib
"Oral Drug in the form of 40 mg tablets - Regorafenib (120 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.~Provided by BAYER"
Placebo
"Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression~Provided by BAYER"
Hôpital La Timone, Marseille
Institut Paoli-Calmettes, Marseille
Centre François Baclesse, Caen
Centre Georges-François LECLERC, Dijon
CHRU Besançon, Besançon
Institut Claudius Regaud, Toulouse
Institut Bergonié, Bordeaux
Institut régional du Cancer de Montpellier, Montpellier
Centre Eugène Marquis, Rennes
Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez
Centre René Gauducheau, Nantes
Institut Godinot, Reims
Centre Oscar Lambret, Lille
Hôpitaux universitaires de Strasbourg, Strasbourg
Centre Léon Bérard, Lyon
Institut Curie, Paris
Centre Henri Becquerel, Rouen
Chu Poitiers, Poitiers
Institut Gustave Roussy, Villejuif
Centre Antoine Lacassagne, Nice
Centre Oscar Lambret
OTHER